Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$0.98−0.05 (-4.49%)
Close on Nov 19, 2026Market cap $98.71MP/E –Yield –
Cellectis operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cellectis's operating income for the twelve months ending Dec 31, 2023 was -$97.30M. For fiscal 2025 it was -$33.08M. The highest annual figure on record is -$6.97M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$33.08M | – |
| FY2024 | Dec 31, 2024 | -$59.55M | – |
| FY2023 | Dec 31, 2023 | -$97.30M | – |
| FY2022 | Dec 31, 2022 | -$89.67M | – |
| FY2021 | Dec 31, 2021 | -$103.48M | – |
| FY2020 | Dec 31, 2020 | -$42.31M | – |
| FY2019 | Dec 31, 2019 | -$123.55M | – |
| FY2018 | Dec 31, 2018 | -$105.09M | – |
| FY2017 | Dec 31, 2017 | -$92.65M | – |
| FY2016 | Dec 31, 2016 | -$67.30M | – |
| FY2015 | Dec 31, 2015 | -$30.98M | – |
| FY2014 | Dec 31, 2014 | -$6.97M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$23.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.59M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.21M | – |
| Q4 FY2023 | Dec 31, 2023 | -$29.58M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.67M | – |
| Q2 FY2023 | Jun 30, 2023 | -$23.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.31M | – |
| Q2 FY2021 | Jun 30, 2021 | -$37.48M | – |
| Q2 FY2020 | Jun 30, 2020 | -$33.03M | – |
| Q2 FY2019 | Jun 30, 2019 | -$35.13M | – |
See a number that looks wrong?